**TRANSFUSION MEDICINE PROTOCOLS**

# Hepatitis B Immunoglobulin VF (for intramuscular use)

**This document should be read in conjunction with the Disclaimer**

| | |
|---|---|
| **AIM** | To describe the indication, ordering, administration and documentation of Hepatitis B Immunoglobulin VF |
| **DESCRIPTION** | Hepatitis B Immunoglobulin-VF for intramuscular injection (IM) |
| **SPECIFICATIONS** | 160 mg/mL plasma proteins (98% immunoglobulins mainly IgG) and 22.5 mg/mL glycine. The solution has a pH of 6.6. At least 98% of the protein is immunoglobulins (mainly IgG), with a hepatitis B antibody titre of not less than 100 IU/mL Manufactured from pooled human plasma.<br>Hepatitis B Immunoglobulin-VF Product Information |
| **VIAL SIZE** | 100 or 400 IU vials of Hepatitis B antibody. |
| **INDICATIONS** | Used to prevent Hepatitis B infection in a person who has come in contact with suspected viral infection. Refer to Hepatitis B Immunoglobulin-VF Product Information for more information.<br>The WNHS Infection Control Manual is available for reference |
| **CONTRAINDICATIONS AND PRECAUTIONS** | Hepatitis B Immunoglobulin-VF is contraindicated in:<br>• Isolated Immunoglobulin A (IgA) deficiency, unless patient is tested and shown not to have circulating anti-IgA antibodies.<br>• Severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.<br>• Patients who are HBsAg-positive.<br>Hepatitis B Immunoglobulin-VF is unnecessary in those who already have adequate circulating hepatitis B antibody (≥10 |

| | |
|---|---|
| | IU/L).<br><br>Refer to Hepatitis B Immunoglobulin-VF Product Information for more information. |
| **CONSUMER INFORMATION** | Hepatitis B Immunoglobulin-VF Consumer Medicine Information |
| **CONSENT** | Manufactured from pooled human plasma. Written consent is required - Refer to Transfusion Medicine Protocol WNHS Blood Product Prescription, Informed Consent. And Refusal |
| **DOSE** | Seek advice from the Clinical Microbiologist or requesting Clinical Haematologist regarding dose.<br><br>• WNHS Hepatitis B in Pregnancy<br>• WNHS Neonatal Hepatitis B Immunoglobulin<br><br>Further dosage information is available in The Australian Immunisation Handbook. Section 4.5.11 Public health management of Hepatitis B and table 4.5.3: Post-exposure prophylaxis for non-immune persons exposed to a HBsAg-positive source |
| **ORDERING** | The Transfusion Medicine Unit (TMU) **must** be contacted and provided with the Patients name, D.O.B and clinical details. If there has been discussion and advice from the Clinical Microbiologist this should also be noted. |
| **ADMINISTRATION** | • Two staff to perform checks as per the Clinical Practice Manual, WNHS Pharmacy Medication Checking and Administration processes.<br>• Check Issue label and patient ID. Check right patient, right product, right dose – prescription matches product supplied. If not identical, contact TMU and prescribing doctor.<br>• The product must be used immediately after opening. Any unused solution must be discarded.<br>• Allow product to reach room temperature before administration.<br>• Do not use the product if it appears turbid or cloudy.<br>• Give slowly by deep inter muscular injection using appropriate sized needle. For more information refer to Hepatitis B Immunoglobulin-VF Product Information. |

| | |
|---|---|
| **OBSERVATIONS** | Undertake observations as for all blood products. Vital signs (temperature, pulse, respiration, blood pressure) must be recorded on the observation chart in the medical record.<br><br>Observe for signs of adverse reactions – refer to Hepatitis B Immunoglobulin-VF Product Information. |
| **ADVERSE REACTIONS** | Local tenderness, erythema and stiffness may occur at the site of injection and may persist for several hours. This may occur after any intramuscular injection. For more information refer to the Hepatitis B Immunoglobulin-VF Product Information.<br><br>Any adverse reaction should be reported to the Clinical Microbiologist/ Haematologist and TMU. Refer to WNHS Management of Transfusion Reactions and Adverse Events, as a guide to further treatment and management of the patient. |
| **DOCUMENTATION** | A record should be kept in the patient's history of the following:<br>• The date and time of infusion<br>• Patients observations and condition during the infusion<br>• Amount given<br>• The batch number and expiry date of each bottle used (place a sticker with the batch number on the Transfusion Medicine Record sheet MR735). This information is important should the patient have a reaction to the infusion or if there is a need to trace recipients of certain batch numbers at a later date. |
| For further information, refer to product insert<br>Return product to TMU immediately if no longer required.<br>Product should be used for intended patient (issue label) only. | |

## References


- Australian Red Cross Blood Service – Blood products and transfusion practice for health professionals. Australian Red Cross website
- Australian Government Department of Health, The Australian Immunisation Handbook, 10th Edition, 2013
- CSL Global Hepatitis B Immunoglobulin-VF
- CSL Hepatitis B Immunoglobulin-VF Product Information

- Australian Red Cross Blood Service – Blood products and transfusion practice for health professionals. http://www.transfusion.com.au/blood_products/fractionated_plasma/immunoglobulins
- Flippin' Blood BloodSafe SA / ARCBS Second Edition June 2012 http://resources.transfusion.com.au/cdm/ref/collection/p16691coll1/id/20

## Related policies

- National Safety and Quality Health Service Standards, October 2012. Standard 7: Blood and Blood Products

## Related WNHS policies, procedures and guidelines

- WNHS Blood Product Prescription, Consent and Refusal
- WNHS Management of Transfusion Reactions and Adverse Events
- WNHS Pharmacy Medication Checking and Administration
- Neonatology Clinical Care Guidelines
- WNHS Hepatitis B in Pregnancy
- WNHS Neonatal Hepatitis B Immunoglobulin
- Obstetrics and Gynaecology Clinical Guidelines
- WNHS Pharmacy Medication Checking and Administration

| | | | |
|---|---|---|---|
| File path: | WNHS.HAEM.HepatitisBImmunoglobulinVF | | |
| Keywords: | Hepatitis Immunoglobulin, hepatitis B immunoglobulin for intramuscular injection, hepatitis B antibody, indications for hepatitis B immunoglobulin, hepatitis B immunoglobulin administration, hepatitis B immunoglobulin for intramuscular use | | |
| Document owner: | Chair of KEMH Hospital Transfusion Committee | | |
| Author / Reviewer: | Consultant Haematologist, Scientist in Charge Transfusion Medicine, KEMH Transfusion Coordinator | | |
| Date first issued: | 01 01 2005 | | |
| Last reviewed: | 01 12 2015 | Next review date: | 01 02 2020 |
| Endorsed by: | KEMH Hospital Transfusion Committee | Date: | 01 02 2017 |
| Standards Applicable: | NSQHS Standards: 1 Governance, 5 Patient ID/Procedure Matching, 7 Blood Products | | |

**Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website.**